KindredBio is focused on next generation veterinary therapeutics: biologics, such as monoclonal antibodies and recombinant proteins.
Next Generation Therapeutics: Biologics
In humans, therapeutic biologics have revolutionized the practice of medicine, providing more effective treatments for many diseases including various cancers as well as inflammatory and autoimmune disorders. KindredBio is focused on development of next generation veterinary therapeutic biologics for cats, dogs, and horses.
Recombinant biologics are produced by inserting the genetic code for a specific therapeutic protein into the DNA of an expression vector in the laboratory. The DNA codes for protein which are inserted into the genome result in production of large quantities of recombinant protein through replication in living host cells in the laboratory. The recombinant protein produced is then purified and the final preparation administered to the animal (cat, dog, or horse) for targeted therapy. The final preparation (drug formulation) is sterile and contains a highly pure and targeted drug. One example of a recombinant protein commonly used in human medicine is erythropoietin alpha (Epogen®).